Phase IIb Protocol 011 Safety Analysis at Week 96: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction

July 18-21, 2021; Virtual
After 24 weeks of 3-drug induction therapy in treatment-naive patients, islatravir plus doravirine dual therapy was generally well tolerated through 96 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 258 KB
Released: July 20, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Slides from CCO: ART in Pregnancy: guideline recommendations and supporting data, pharmacokinetic considerations, and drug-drug interactions

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Jonah Musa, MBBS, MSCI, PhD Released: October 20, 2021

Clinical Care Options (CCO) expert analysis of new HIV data from IDWeek 2021, provided by expert HIV faculty

Darcy Wooten, MD Released: October 20, 2021

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Dr William Short and Clinical Care Options (CCO): Data fails to support adding agents to intensify ART, switching ART, or adding IL-2 for patients with suboptimal CD4+ cell counts on suppressive ART

William R. Short, MD, MPH, AAHIVS Released: October 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue